A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis

Abstract

In the LOLA group, an improvement of posturographic control and PSE Syndrome Test was observed, but a similar improvement was also achieved by the placebo. In LOLA, ammonia levels tended to decrease while they tended to increase in the placebo group. LOLA might augment the improvement achieved by intravenous fluids alone but a larger cohort will be needed to show this effect with statistical significance.

Effects of supplementation with branched chain amino acids and ornithine aspartate on plasma ammonia and central fatigue during exercise in healthy men

“…Supplements based on proteins and amino acids are currently one of the most overused and overdosed, so any recommendations for their use should be calculated very carefully. In certain cases the use of OA seems to be rational and in agreement with the results of most studies [1,7,8,11,42,44]; however, some critical works are also present [2,45].…”

Hepatic encephalopathy: features of pharmacotherapy

“…Улучшение показа-телей психометрических тестов среди получавших L-орнитин-L-аспартат статистически значимо превы-шало таковое в группе плацебо. Уровень аммиака сни-зился в группе пациентов, получавших препарат, в то время как в контрольной группе отмечено незначи-тельное повышение [32]. Анализ публикаций, посвященных исследованию эффективности и безопасности L-орнитина-L-аспартата, свидетельствует об эффективности препарата в отноше-нии уменьшения клинических проявлений ПЭ, а также снижения концентрации аммиака [33].…”

Management of Covert Hepatic Encephalopathy

“…63 Given the small sample size of studies evaluating LOLA, there is a risk of publication bias; therefore the role of LOLA in the management of CHE should be interpreted with caution.…”